In the case of ovarian carcinoma and multiple myeloma cells, the enhancement of TP53 expression was also demonstrated against the background of the antitumor effect of different GnRH-I agonists and antagonists [30,55]. The gene discussed is GNRH1; the disease is plasma cell myeloma.